Beresniak Ariel, Medina-Lara Antonieta, Auray Jean Paul, De Wever Alain, Praet Jean-Claude, Tarricone Rosanna, Torbica Aleksandra, Dupont Danielle, Lamure Michel, Duru Gerard
Data Mining International, Route de l'Aéroport, 29-31, CP 221, 1215, Geneva 15, Switzerland,
Pharmacoeconomics. 2015 Jan;33(1):61-9. doi: 10.1007/s40273-014-0216-0.
Quality-adjusted life-years (QALYs) have been used since the 1980s as a standard health outcome measure for conducting cost-utility analyses, which are often inadequately labeled as 'cost-effectiveness analyses'. This synthetic outcome, which combines the quantity of life lived with its quality expressed as a preference score, is currently recommended as reference case by some health technology assessment (HTA) agencies. While critics of the QALY approach have expressed concerns about equity and ethical issues, surprisingly, very few have tested the basic methodological assumptions supporting the QALY equation so as to establish its scientific validity.
The main objective of the ECHOUTCOME European project was to test the validity of the underlying assumptions of the QALY outcome and its relevance in health decision making.
An experiment has been conducted with 1,361 subjects from Belgium, France, Italy, and the UK. The subjects were asked to express their preferences regarding various hypothetical health states derived from combining different health states with time durations in order to compare observed utility values of the couples (health state, time) and calculated utility values using the QALY formula.
Observed and calculated utility values of the couples (health state, time) were significantly different, confirming that preferences expressed by the respondents were not consistent with the QALY theoretical assumptions.
This European study contributes to establishing that the QALY multiplicative model is an invalid measure. This explains why costs/QALY estimates may vary greatly, leading to inconsistent recommendations relevant to providing access to innovative medicines and health technologies. HTA agencies should consider other more robust methodological approaches to guide reimbursement decisions.
自20世纪80年代以来,质量调整生命年(QALYs)一直被用作进行成本效用分析的标准健康结果衡量指标,而成本效用分析常常被不恰当地称为“成本效益分析”。这种综合结果将生命的数量与以偏好分数表示的质量相结合,目前被一些卫生技术评估(HTA)机构推荐为参考案例。虽然QALY方法的批评者对公平性和伦理问题表示担忧,但令人惊讶的是,很少有人对支持QALY等式的基本方法假设进行检验,以确定其科学有效性。
ECHOUTCOME欧洲项目的主要目标是检验QALY结果基本假设的有效性及其在健康决策中的相关性。
对来自比利时、法国、意大利和英国的1361名受试者进行了一项实验。受试者被要求表达他们对通过将不同健康状态与持续时间相结合得出的各种假设健康状态的偏好,以便比较(健康状态,时间)组合的观察到的效用值和使用QALY公式计算的效用值。
(健康状态,时间)组合的观察到的和计算出的效用值存在显著差异,这证实了受访者表达的偏好与QALY理论假设不一致。
这项欧洲研究有助于确定QALY乘法模型是一种无效的衡量方法。这就解释了为什么成本/QALY估计值可能差异很大,导致在提供创新药物和健康技术的获取方面的建议不一致。HTA机构应考虑其他更可靠的方法来指导报销决策。